Mon, Apr 21, 2014, 9:40 AM EDT - U.S. Markets close in 6 hrs 20 mins


% | $
Quotes you view appear here for quick access.

Alnylam Pharmaceuticals, Inc. Message Board

SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • This stock is just another dream. The earliest it can have a commercial product is mid 2016. By then QE will be over, interest rates will climb, and the market will be who knows where. The present valuation reminds me of the internet bubble in 1999-2000. The biotech bubble will pop sometime soon too.

  • I don't think a lot of people outside the pharma industry (even in the medical community) understand how groundbreaking and transformative the technology of RNAi truly is. Since the 90's, the pharma industry has been diddling around with drug development strategies that were not truly targeted or had intentional results.

    First, it was "rational drug design" which was too theoretical, lengthy and therefore expensive.

    Then there was "combinatorial chemistry" for drug design which was the "throw everything at the wall and see what sticks" approach.

    Genomics opened up new ways to target disease, but you have to tinker with DNA, which we are still learning how to do because we don't understand how the functions of some genes affect the functioning of other genes.

    HOWEVER, RNA interference is THE breakthrough. Genes (DNA) encode proteins, and proteins have functions. RNA is the biological molecule responsible for translating the DNA into a protein. Until now, diseases that are caused by particular proteins, and which could be cured by reducing he production of that protein, could not be remedied because there was no good way to STOP the production of the protein, other than tinkering with the DNA that encoded it. RNAi allows the DNA (genes) to remain intact, but interferes with the translator and stops the protein from being expressed and produced. Stop the protein, stop the disease.

    This drug development approach is such a big deal because ALL diseases are influenced in some way - in fact all bodily functions and metabolism is controlled by this very fundamental process of producing protein mediated by RNA, that this approach to developing drugs has revolutionary potential for treating disease.

    I don't often post, and clearly I am pumping, but I backed up the truck at 10 ish because this is one of those rare opportunities to invest in something with ACTUAL prospects. They say to invest in what you know. I'm glad nobody else knows the potential of RNAi ! ! !

  • The secret is that both ALNY and ISIS are both strong buys.
    Larger companies are trying to get the stock "ALAP" AS LOW AS POSSIBLE to create a fantastic entry point FOR THEMSELVES.
    But don't take my word for it. Take a look for yourself at some of the sneaky techniques only large companies can afford to do to manipulate the stock in their favour.
    Let me give you just one example of what I mean and in my next post I will talk about the weasle words that some analysts use to scare the millions of small investors into selling too soon and in turn selling themselves short of what will eventually be a $200 stock.
    Example 1 of not so obvious yet powerful Manipulation:
    Look back to previous After Hours trading sessions for either ALNY or ISIS. If you did not look very carefully you would think to yourself "Oh No!" the price is going down. After all if it shows the stock price as lower, then investors must think that the stock has dropped due to an average consensus of value, Right?... WRONG!!!!!!Large companies actually purchase incredibly tiny volumes of shares. Sometimes quantities as low as 10, 5 or even a single (1) share. It turns out that if you were to place a sell order at $60 for a even a single share in an After Hours session it will show that $60 is the current share price for all of Alnylam. Go to Nasdaq and Look at the actual trades one by one and you will clearly see their sneaky manipulative game in action. You will see that they do this the most right before the After Hours trading session finishes just so that the last stock price is exactly set at what they want to show it at, which of course will set the tone for the next morning's opening trade. Look for yourself in the next after hours trading session on Nasdaq's website as it happens and don't let them fool you into selling a valuable stock for less than its true value ever again.

    Sentiment: Strong Buy

  • the dump begins

  • Reply to

    No Drug on the Market for at least 2 Years

    by hundleyrandy Feb 20, 2014 3:33 PM

    Do you have a clue of what you are saying? This stock s changing medicine as we know it. This thing has just begun it's move. It will be up 5-10 fold in 3-5 years.

  • This is the last dip of the bottom out and then it will go up high. Stay strong and don't sell according to analyst Steve Reitmeister from Zacks Profit From The Pros. Don't give food to the vultures as this is only a temporary dip.
    He Says "This could just be a terrifying intraday drop that sparks a final capitulation.

    So in my book, this is not a downward move worth trading. Instead I recommend already being 100% long in preparation for a likely return visit to previous highs. And if all goes well with earnings season, then perhaps probe above 1900 for a while"

  • From investorvillage: "ALNY: Alnylam outlook not affected by Novartis decision, says JMP

    Alnylam outlook not affected by Novartis decision, says JMP Securities
    After Novartis (NVS) discontinued its RNAi drug discovery program, JMP
    Securities does not think the decision should affect the potential of Alnylam's
    (ALNY) pipeline. The firm believes that Novartis' inability to figure out RNAi
    technology - and not problems with RNAi as a whole - led to Novartis' decision.
    The firm reiterates a $110 price target and Outperform rating on Alnylam."

    Sentiment: Strong Buy

  • Reply to

    ALNY Catalysts in 2014? Longs please help

    by chirag_487a Apr 12, 2014 12:57 PM

    two major have already occurred... Sanofi investing awhopping 700 million
    dollars at $ 80 per share... and Gnezyme adding another 35 millions shares
    at $ 68 per share just 2 weeks ago... I think at these levels owning this stock is
    a NO brainer... she may go down a bit more along with the bio tech dump.. but
    when the selling is over.. she can bounce back violently.. I see $ 90++ by year
    end easy... and $ 125 within 2-3 years... almost 250% return from here..
    risk reward at these levels is fantastic..... own it without ANY worries.. add more
    if she dips below 50..

  • Reply to

    No Drug on the Market for at least 2 Years

    by hundleyrandy Feb 20, 2014 3:33 PM

    Hey Nimrod - They have ONE BILLION in Cash to fund them for many years - you are a clueless idiot. Beat it Creep.

  • Reply to

    No Drug on the Market for at least 2 Years

    by hundleyrandy Feb 20, 2014 3:33 PM

    You may be right. It just might be time to sit on the sidelines for a while. been debating just that. My average under $10. long term makes is a little easier.

    As for the bio bubble, I think you are mistaken when it comes to RNAi. The promise is quickly becoming reality.

    Might want to take a look at RXII, wll be in ALNY's league before too long.............good luck All

  • Reply to

    No Drug on the Market for at least 2 Years

    by hundleyrandy Feb 20, 2014 3:33 PM

    You are out of your mind. I've been investing in biotechs for over 20 years. I know an overvalued hype play when I see it. The first indication for this which company is pursuing is small. Yes they have good data, but the P3 clinical trial isn't going to be completed for 18 months. It is going to take another 6 months to compile the data and get the NDA filed. Then it is going to take 6 months more for an FDA decisionl. So you are looking at 30 months or 2.5 years. And then when they get approval, if they do, sales are going to be small. The only thing driving this stock is the new money entering the market as a result of QE. Well my friend that is coming to an end and so too will this overvalued stock price. And on top of all this, you have Obamacare totally screwing up the healthcare in this country. If you like to gamble with your money, this is the stock.

  • down graded by 4 houses. filed CT SHORT THIS NOW

    Sentiment: Strong Sell

  • by May 17. BUY

  • She needs to first fill the gap at 68.. which she might next week.. then
    a little haggling around 80-82 area.. a stubborn resistance at 91
    once she clears 91... nonstop express to 110. All this will take
    a good 3-6 months.. so patience...

  • IMO anyway. Now we find out if they were holding it up for valuation purposes..

  • Reply to

    why sell?

    by ydobrovic Apr 10, 2014 12:29 PM

    Great point! This is what Zacks wrote today " there was never a sound fundamental reason underpinning the decline in the first place."

    Sentiment: Strong Buy

  • been with this company from nearly it's inception. Will surprise us even more this year IMHO.

  • Reply to

    Novartis Slams on Breaks

    by charley472002 Apr 14, 2014 1:50 PM

    that is good news for ALNY.. it consolidates her position as a leader...

  • For the short term, Alnylam is delivering two Plenary oral presentations and one poster on April 30:
    Patisiran; International Symposium on Amyloidosis (ISA), April 27 - May 1. One Plenary paper further analyzes Phase 2 data of Patisiran.

    Pending acceptance, more papers will be presented in the following meetings.
    ALN-PCSsc; Arteriosclerosis, Thrombosis, and Vascular Biology, May 1 - 3
    ALN-AAT; Digestive Disease Week, May 4 - 6
    ALN-AT3; World Federation on Hemophilia, May 11 - 14
    ALNY 5X15; TIDES, May 12 - 15
    ALN-CC5; International Conference on Complement Therapeutics, June 6 - 11

    For the time frame of October – December, look up my post of March 29: [[ When the data from ALN-AT3 for hemophilia A and B, -TTR02 for FAP, and -TTRsc for FAC come out, the share price could triple from here.]]

  • Think about it !

    Sentiment: Sell

53.29-0.57(-1.06%)9:40 AMEDT

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.